Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most
Background Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) trial (NCT02329327). However, little...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Stroke: Vascular and Interventional Neurology |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/SVIN.123.000997 |
| _version_ | 1797322640565731328 |
|---|---|
| author | Mauricio Concha Lizhen Xu MacKenzie Horn Tomoyuki Ohara Juliet Nakamya Jan Beyer‐Westendorf Ashkan Shoamanesh Alexander Cohen Per Ladenvall Stuart J. Connolly Andrew M. Demchuk |
| author_facet | Mauricio Concha Lizhen Xu MacKenzie Horn Tomoyuki Ohara Juliet Nakamya Jan Beyer‐Westendorf Ashkan Shoamanesh Alexander Cohen Per Ladenvall Stuart J. Connolly Andrew M. Demchuk |
| author_sort | Mauricio Concha |
| collection | DOAJ |
| description | Background Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) trial (NCT02329327). However, little is known about predictors associated with hematoma expansion in patients with factor Xa inhibitor–associated intracranial hemorrhage (ICrH) receiving andexanet alfa. Methods The ANNEXA‐4 trial was a prospective, single‐arm, open‐label study of andexanet alfa in patients with acute major bleeding within 18 hours after taking a factor Xa inhibitor. Hematoma volumes at baseline and 12 hours after andexanet alfa treatment were measured using a computerized‐assisted volumetric method. Univariable and multivariable logistic regression analyses of clinical and nonclinical parameters were performed to identify factors predictive of different volumes of hematoma expansion. To this end, an ICrH Expansion Scale was developed. Results Overall, 305 ANNEXA‐4 study patients with baseline and follow‐up imaging were included, 15.7% of whom showed evidence of any ICrH expansion ≥6‐mL. Patients with ≥6‐mL ICrH expansion had a significantly (P<0.05) higher proportion of ICrH with multiple compartment involvement (36% versus 14.3%); shorter times from symptom onset to baseline computed tomography (median, 1.6 hours [interquartile range (IQR), 1.2–4.3 hours] versus 3.7 hours [IQR, 1.6–7.0 hours]); lower Glasgow Coma Scale scores (14 [IQR, 12–15] versus 15 [IQR, 14–15]); higher systolic blood pressure 15 minutes before andexanet alfa bolus (mean, 151.6 mm Hg [SD, 24.1 mm Hg] versus 143.3 mm Hg [SD, 22.3 mm Hg]); and larger median baseline ICrH volumes (29.3 mL [IQR, 13.3–50.8 mL] versus 8.6 mL [IQR, 2.1–22.4 mL]). Multivariable analysis confirmed shorter symptom onset‐to‐computed tomography time and larger ICrH volume as independent predictors of ≥6‐mL growth and ICrH Expansion Scale change. Lower Glasgow Coma Scale showed a trend (P = 0.06) as an independent predictor of ≥6‐mL growth but was an independent predictor of ICrH Expansion Scale change. Conclusion Shorter time from symptom onset to computed tomography, larger hematoma volumes, and lower Glasgow Coma Scale score at presentation increased the risk of ICrH expansion in patients with factor Xa inhibitor–associated ICrH treated with andexanet alfa. |
| first_indexed | 2024-03-08T05:17:16Z |
| format | Article |
| id | doaj.art-9afe5c2bf3dd4bf3923c253ead8387eb |
| institution | Directory Open Access Journal |
| issn | 2694-5746 |
| language | English |
| last_indexed | 2024-03-08T05:17:16Z |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stroke: Vascular and Interventional Neurology |
| spelling | doaj.art-9afe5c2bf3dd4bf3923c253ead8387eb2024-02-06T17:23:07ZengWileyStroke: Vascular and Interventional Neurology2694-57462024-01-014110.1161/SVIN.123.000997Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter MostMauricio Concha0Lizhen Xu1MacKenzie Horn2Tomoyuki Ohara3Juliet Nakamya4Jan Beyer‐Westendorf5Ashkan Shoamanesh6Alexander Cohen7Per Ladenvall8Stuart J. Connolly9Andrew M. Demchuk10Sarasota Memorial Hospital Sarasota FLMcMaster University Hamilton Ontario CanadaCalgary Stroke Program, Departments of Clinical Neurosciences and Radiology Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary Calgary Alberta CanadaDepartment of Neurology Kyoto Prefectural University of Medicine Kyoto JapanMcMaster University Hamilton Ontario CanadaUniversity Hospital Carl Gustav Carus Dresden GermanyMcMaster University Hamilton Ontario CanadaGuys and St. Thomas Hospitals, King's College London London UKBiopharmaceuticals Research and Development AstraZeneca Gothenburg SwedenMcMaster University Hamilton Ontario CanadaCalgary Stroke Program, Departments of Clinical Neurosciences and Radiology Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary Calgary Alberta CanadaBackground Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) trial (NCT02329327). However, little is known about predictors associated with hematoma expansion in patients with factor Xa inhibitor–associated intracranial hemorrhage (ICrH) receiving andexanet alfa. Methods The ANNEXA‐4 trial was a prospective, single‐arm, open‐label study of andexanet alfa in patients with acute major bleeding within 18 hours after taking a factor Xa inhibitor. Hematoma volumes at baseline and 12 hours after andexanet alfa treatment were measured using a computerized‐assisted volumetric method. Univariable and multivariable logistic regression analyses of clinical and nonclinical parameters were performed to identify factors predictive of different volumes of hematoma expansion. To this end, an ICrH Expansion Scale was developed. Results Overall, 305 ANNEXA‐4 study patients with baseline and follow‐up imaging were included, 15.7% of whom showed evidence of any ICrH expansion ≥6‐mL. Patients with ≥6‐mL ICrH expansion had a significantly (P<0.05) higher proportion of ICrH with multiple compartment involvement (36% versus 14.3%); shorter times from symptom onset to baseline computed tomography (median, 1.6 hours [interquartile range (IQR), 1.2–4.3 hours] versus 3.7 hours [IQR, 1.6–7.0 hours]); lower Glasgow Coma Scale scores (14 [IQR, 12–15] versus 15 [IQR, 14–15]); higher systolic blood pressure 15 minutes before andexanet alfa bolus (mean, 151.6 mm Hg [SD, 24.1 mm Hg] versus 143.3 mm Hg [SD, 22.3 mm Hg]); and larger median baseline ICrH volumes (29.3 mL [IQR, 13.3–50.8 mL] versus 8.6 mL [IQR, 2.1–22.4 mL]). Multivariable analysis confirmed shorter symptom onset‐to‐computed tomography time and larger ICrH volume as independent predictors of ≥6‐mL growth and ICrH Expansion Scale change. Lower Glasgow Coma Scale showed a trend (P = 0.06) as an independent predictor of ≥6‐mL growth but was an independent predictor of ICrH Expansion Scale change. Conclusion Shorter time from symptom onset to computed tomography, larger hematoma volumes, and lower Glasgow Coma Scale score at presentation increased the risk of ICrH expansion in patients with factor Xa inhibitor–associated ICrH treated with andexanet alfa.https://www.ahajournals.org/doi/10.1161/SVIN.123.000997andexanet alfaanti‐factor Xa activitydirect factor Xa inhibitor reversalhematoma expansionintracranial hemorrhage |
| spellingShingle | Mauricio Concha Lizhen Xu MacKenzie Horn Tomoyuki Ohara Juliet Nakamya Jan Beyer‐Westendorf Ashkan Shoamanesh Alexander Cohen Per Ladenvall Stuart J. Connolly Andrew M. Demchuk Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most Stroke: Vascular and Interventional Neurology andexanet alfa anti‐factor Xa activity direct factor Xa inhibitor reversal hematoma expansion intracranial hemorrhage |
| title | Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most |
| title_full | Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most |
| title_fullStr | Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most |
| title_full_unstemmed | Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most |
| title_short | Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most |
| title_sort | predictors of intracranial hemorrhage volume expansion in patients receiving factor xa inhibitors in annexa 4 time and severity matter most |
| topic | andexanet alfa anti‐factor Xa activity direct factor Xa inhibitor reversal hematoma expansion intracranial hemorrhage |
| url | https://www.ahajournals.org/doi/10.1161/SVIN.123.000997 |
| work_keys_str_mv | AT mauricioconcha predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost AT lizhenxu predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost AT mackenziehorn predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost AT tomoyukiohara predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost AT julietnakamya predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost AT janbeyerwestendorf predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost AT ashkanshoamanesh predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost AT alexandercohen predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost AT perladenvall predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost AT stuartjconnolly predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost AT andrewmdemchuk predictorsofintracranialhemorrhagevolumeexpansioninpatientsreceivingfactorxainhibitorsinannexa4timeandseveritymattermost |